A clinical trial to study the effect of two drugs, metoclopramide and dexamethasone which are used to prevent nausea and vomiting in patients who wants to have child through operation.

COMPARATIVE STUDY TO DETERMINE THE PROPHYLACTIC EFFICACY OF METOCLOPRAMIDE AND DEXAMETHASONE ON INTRA AND POST OPERATIVE NAUSEA AND VOMITING IN ELECTIVE CESAREAN SECTION UNDER SPINAL ANAESTHESIA

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/09/045782

Enrollment

100

Registered

2022-09-22

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O00-O9A- Pregnancy, childbirth and the puerperium

Interventions

Intervention1: Dexamethasone (Intravenous route): Injection Dexamethasone 8mg given in patients undergoing cesarean section under spinal anaesthesia Control Intervention1: Metoclopramide (Intravenous

Eligibility

Inclusion criteria

Inclusion criteria: Patient giving consent to participate in study, Age between 18-35 year, Patient of female sex, ASA grade I and II, Patient scheduled for elective cesarean section.

Exclusion criteria

Exclusion criteria: Patients not giving consent to participate in the study, ASA grade III and IV, Episode of vomiting prior umbilical cord clamping, Patient with known hyperemesis, Surgery under GA, Use of opioids, Body mass index (BMI) >35, below 18 years and above 35 years of age, Evidence of intrauterine growth retardation, Any antiemetic treatment within 24 h before surgery,History of motion sickness, Gastrointestinal disease, Allergy to the study drugs

Design outcomes

Primary

Measure	Time frame
10mg METOCLOPRAMIDE given intravenously is more effective,safe and cheap to prevent nausea and vomiting intraoperatively Timepoint: 24 weeks	—

Secondary

Measure	Time frame
Metoclopramide is a better drug for preventing nausea and vomiting with minimal side effects.Timepoint: 24 weeks	—

Countries

India

Contacts

Public ContactDr Suman Gupta

Gajra Raja Medical College

sumangupta02@rediffmail.com9981962454

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026